Introduction: Acharya Sushruta
describes six patala in Netra in which 2 Bahya vartma patala and 4 patala in
netra - tejo Jalashrita, Pishitashrita, medoashrita, and last Ashtiashrita,
dosha enters in 1st and 2nd patala it’s called Timir. Dalhana described,
Tejo-jalashrita patala Teja means alochaka pitta situated in siragata rakta,
jala means twachagata rasa dhatu. According to Acharya
Sushruta Timir causing dosha when reach internal orbital organs through the
sira and occupies pratahama patala causing blurring of vision, pratahama
patalagata timira vitiates the superficial dhatu. Acharya Sushruta has
mentioned Vedhana karma one of the Ashtvidha shastra karma. Here the meaning of
Viddha or Vedhana – is to pierce or penetrate something. Acharya Vagbhat
Describe Anjana types, form, matra, kal and according to dosha use of Anjana
karma in sutra sthana chapter 23. For all types of
Timir Acharya Vagbhat describe Akshabeejadi Anjana in Uttartantra. According to a study
by NCBI, the prevalence of myopia in India varies between 3.6% and 36.5%
depending on the type of study. Population-based studies have a prevalence rate
of 3.6% to 36.5%, while school-based studies have a rate of 7.5% to 8.6%, and
hospital-based studies have a rate of 9%. Most of these studies include people
under the age of 40. Myopia, commonly
referred to as short-sightedness, is the most common eye disease in the world
with a substantial social, educational, and economic impact on the affected
one.
Simple myopia can be
corrected with spectacles or contact lenses, whereas pathological myopia is
often associated with potentially blinding conditions such as retinal
detachment or macular degeneration. Origin of the
Research Problem: In modern science,
the best option for myopia is wearing glasses or contact lens for myopia. Another option is
LASIK surgery but light sensitivity develops after LASIK surgery complications
like Dry eye. So, we can search for
alternative medicine Vedhana karma comparison with Akshabeejadi Anjana and add
on effect of Vedhana Karma. Key Questions: 1. Only Vedhana karma is Effective in
Prathama Patalagata Timir (Myopia <-6D) 2. Only Akshabeejadi Anjana is effective
in Prathama Patalagata Timir (Myopia <-6D)
3. Add-on effect of Vedhana karma with
Akshabeejadi Anjana more effective in Prathama Patalagata Timir (Myopia
<-6D) Hypothesis: Null hypothesis (H0) Vedhana karma and
Akshabeejadi Anjana have no significant effect in Prathama Patalagata Timir
(Myopia <-6D) Alternative
hypothesis (Ha) Vedhana karma and
Akshabeejadi Anjana having significant effect in Prathama Patalagata Timir
(Myopia <-6D) Objectives: Primary 1. To study the etiopathology of Prathama
Patalagata Timir in Ayurveda and Modern. 2. To evaluate the effect of Vedhana Karma
in Prathama Patalagata Timir (Myopia -<6D) Secondary 1. To evaluate the effect of Akshabeejadi
Anjana in Prathama Patalagata Timir (Myopia -<6D) 2. To evaluate the effect of Vedhana Karma
with Akshabeejadi Anjana in Prathama Patalagata Timir (Myopia -<6D). Research Gap/Review
of Literature (International Status/National Status and scope of the proposal): The treatment of
myopia (comparable to Prathama Patalagata Timira) has undesirable aspects such
as the permanent use of spectacles. Akshabeejadi Anjana
is one of the effective treatments of Timir.
Vedhana karma,
despite being simple and easy to do, remains unexplored in this condition. Methodology: Study design - Open
Labelled Randomized Comparative Clinical Study. Group A Vedhana karma Group B Akshabeejadi
Anjana Group C Vedhana karma
& Akshabeejadi Anjana Sample size total –
138 (Each group 46 Patients Group A 46, Group B 46 and Group C 46) Inclusive criteria Patients with myopia
< -6D in at least one eye, diagnosed as per ICD-10-CM Diagnosis Code H52.1
& H52.2 (Simple myopic astigmatism) Age 18-30 years Both Gender Exclusive criteria Myopia >-6D Patient having
diseases of Corneal, Choroid, Vitreous, retinal and ciliary muscle Contraindicated for
Vedhana Karma and Anjana Systemic diseases
like DM, Hypertension, Trauma, etc.
Patient is on
medication for a blood thinner |